Business
Emerging Growth Research Reiterates Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Q3:25 Results
New York, New York--(Newsfile Corp. - December 1, 2025) - Emerging Growth Research today announced the release of its Q3:25 quarterly update on SBC Medical Group Holdings, Inc. (NASDAQ: SBC), reiterating a Buy-Extended rating and maintaining its 12-month price target of $9.00, representing significant upside from the Company's recent closing price of $3.57 on November 28, 2025.The quarterly update highlights SBC's sequential stabilization in revenue and operating profit during Q3:25, strong cash
About this update from Sbc Medical Group Holdings Incorporated
[{"type":"text","content":"New York, New York--(Newsfile Corp. - December 1, 2025) - Emerging Growth Research today announced the release of its Q3:25 quarterly update on SBC Medical Group Holdings, Inc. (NASDAQ: SBC), reiterating a Buy-Extended rating and maintaining its 12-month price target of $9.00, representing significant upside from the Company's recent closing price of $3.57 on November 28, 2025.","length":384,"tagName":"p"},{"type":"text","content":"The quarterly update highlights SBC's sequential stabilization in revenue and operating profit during Q3:25, strong cash position, and the Company's positioning for renewed growth beginning in early 2026 as it works through near-term competitive pressures.","length":264,"tagName":"p"},{"type":"text","content":"Key Highlights from the Q3:25 Update Report:","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue Stabilization: Q3:25 revenue of $43.4 million remained flat sequentially versus Q2:25, while down (18)% year-over-year due to revised franchising fee structures. Management expects stabilization to continue through Q1:26 before returning to historical growth rates.","length":273,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating Profit Growth: Operating profit rose to $15.9 million in Q3:25, up from $13.8 million in Q3:24 and $14.6 million sequentially in Q2:25, demonstrating effective cost management despite revenue pressures.","length":212,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong Volume Growth: The Company added 34 new clinic locations year-over-year (reaching 258 total clinics) and grew annual customer visits to 6.5 million with a 72% repeat rate. Average revenue per visit increased to $298 in Q3:25 from $275 in Q1:25.","length":251,"tagName":"p"}]},{"val":[{"type":"text","content":"Robust Balance Sheet: SBC ended Q3:25 with $127 million in cash, plus $83 million in accounts receivable and $15 million in prepaid expenses, against only $21 million in long-term debt. Net cash represents approximately 40% of the Company's current market capitalization.","length":275,"tagName":"p"}]},{"val":[{"type":"text","content":"Path to Growth: Management anticipates revenue will resume its historical +10% to +15% CAGR beginning in 2026, supported by domestic organic growth, the goal of expanding from 258 to 1,000 clinics over te...